Cumulatively, there are more than 10,000 rare diseases affecting over 30 million Americans. 70% of these diseases begin in childhood, and 72% of them have a genetic basis. Additionally, nearly 1 out of 5 cancers is considered rare. Unfortunately, many rare disease patients face significant challenges before receiving a proper diagnosis, and even after diagnosis, effective therapies can be lacking.

At Clinakos Inc., we remain dedicated to the rare disease community. Through our collaborations with patient advocacy groups, providers, and life science companies, we strive to bring groundbreaking solutions to this area. Our proprietary capabilities, including Integrated Patient Data™ and Smart AI™, are designed to address the unique needs of rare diseases, oncology, and niche subpopulations. If you identify an opportunity for collaboration, please don’t hesitate to reach out to us.